This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)

Tipranks - Tipranks - Tue Jun 23, 5:54AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS) with bullish sentiments.

TipRanks' Prime Week Sale - 70% Off

Zymeworks (ZYME)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Zymeworks, with a price target of $46.00. The company’s shares closed last Thursday at $23.14.

According to TipRanks.com, Burns is a 5-star analyst with an average return of 20.6% and a 47.5% success rate. Burns covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, BridgeBio Oncology Therapeutics, and Black Diamond Therapeutics. ;'>

Zymeworks has an analyst consensus of Strong Buy, with a price target consensus of $38.71, representing a 65.9% upside. In a report issued on June 9, Truist Financial also initiated coverage with a Buy rating on the stock with a $28.00 price target.

See today’s best-performing stocks on TipRanks >>

Maze Therapeutics, Inc. (MAZE)

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $110.00. The company’s shares closed last Thursday at $25.68.

According to TipRanks.com, Ghosh is a 4-star analyst with an average return of 15.7% and a 42.0% success rate. Ghosh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, ACADIA Pharmaceuticals, and Annexon Biosciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Maze Therapeutics, Inc. with a $63.56 average price target.

Universal Health (UHS)

In a report released today, Ryan Langston from TD Cowen maintained a Buy rating on Universal Health, with a price target of $197.00. The company’s shares closed last Thursday at $141.17.

According to TipRanks.com, Langston has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.4% and a 39.7% success rate. Langston covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Privia Health Group, and P3 Health Partners. ;'>

Currently, the analyst consensus on Universal Health is a Moderate Buy with an average price target of $213.31, a 49.8% upside from current levels. In a report issued on June 20, TipRanks – OpenAI also upgraded the stock to Buy with a $157.00 price target.

Read More on ZYME:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).